Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rang în acțiuni #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Preț acțiune
$22.26
Ultima sincronizare: 2024-03-22
Capitalizare de piață
$553.40M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Graphite Bio, Inc. (GRPH)

Categorie

Raport P/S pentru Graphite Bio, Inc. (GRPH)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Graphite Bio, Inc., raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Graphite Bio, Inc. din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH